{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:46:22Z","timestamp":1793108782056,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    There are some evidences that hypogammaglobulinemia in newly diagnosed diffuse large B cell lymphoma (DLBCL) is a predictor for inferior outcome, but the risk for infection\u2010related admissions specifically related to hypogammaglobulinemia is not known. The aim was to explore if hypogammaglobulinemia in untreated DLBCL in a Swedish cohort was associated with inferior outcome, and to assess the relationship between low immunoglobulin (Ig) levels and infections. Using data from the Swedish Lymphoma Register, we retrospectively identified patients above18\u00a0years diagnosed with DLBCL, receiving anthracycline\u2010based curative therapy during 2000\u20132015 in Southern Sweden with Ig\u2010levels tested at baseline. Data on Ig levels and infections were collected from medical records. Five hundred eighty\u2010five patients were included, median age was 69\u00a0years. Hypogammaglobulinemia was detected at baseline in 24%, the most common Ig deficiency was IgG (18%), followed by IgA (10%) and IgM (8%). Hypogammaglobulinemia was associated with inferior overall survival (HR 1.4, 95% CI 1.0\u20131.8,\n                    <jats:italic>p<\/jats:italic>\n                    \u2010value 0.018), but not when adjusted for International Prognostic Index (IPI). Low levels of Ig were associated with more infections during lymphoma treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2010value 0.013), also when adjusted for IPI (\n                    <jats:italic>p<\/jats:italic>\n                    \u2010value &lt; 0.001). Among patients with IgG deficiency, 47% had \u2265 1 infections versus 35% in patients with normal IgG (HR 1.2,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.025). In conclusion, hypogammaglobulinemia was a frequent finding in patients with newly diagnosed DLBCL, with clinical impact in terms of treatment complications and outcome.\n                  <\/jats:p>","DOI":"10.1002\/hon.70014","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:08:17Z","timestamp":1733270897000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-4797","authenticated-orcid":false,"given":"A\u030asa","family":"Lindberg","sequence":"first","affiliation":[{"name":"Internal Medicine and Hematology Halland Hospital Halmstad  Halmstad Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u030asa","family":"Johansson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transfusion Medicine Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Kahn","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Ska\u030ane University Hospital and Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Jo\u0308nsson","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Ska\u030ane University Hospital and Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Division of Oncology Ska\u030ane University Hospital and Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.944"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010017\u20103747\u2010z"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25332"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.11.1493"},{"key":"e_1_2_8_9_1","unstructured":"Sweden CoRCCi. Aggressiva B\u2010cellslymfom Nationell v\u00e5rdprogram [Web page].Version 6.0:[National Clinical Care Guidelines for DIffuse Large B\u2010Cell Lymphoma]. [updated 2023\u201001\u201025;2023\u201001\u201025] https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/aggressiva\u2010b\u2010cellslymfom\/vardprogram\/2023."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.413"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107365"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935\u2010021\u201001978\u2010w"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1617861"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201010\u20103411"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.164"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02403"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.947"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449251"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122737"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1832673"},{"key":"e_1_2_8_23_1","unstructured":"U.S. Department of Health and Human Services NIoH National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.2009."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp505"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404780"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100609.2008.01129.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004286"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928062"},{"key":"e_1_2_8_29_1","unstructured":"Support NCK. Nationellt kliniskt kunskapsst\u00f6d Prim\u00e4r immunbrist 2022 [updated 2024\u201003\u201013].2022 https:\/\/www.nationelltklinisktkunskapsstod.se\/Norrbotten\/kunskapsstod\/kliniskakunskapsstod\/?uuid=001bf6c6\u2010cdde\u20104836\u20108867\u2010842c1133af5a&selectionCode=profession_primarvard."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.09.003"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563214545791"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.02.040"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.006"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T15:21:59Z","timestamp":1738164119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/hon.70014"],"URL":"https:\/\/doi.org\/10.1002\/hon.70014","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.70014\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70014\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70014\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"2024-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70014"}}